Document Detail


Genome-wide screening for drug discovery and companion diagnostics.
MedLine Citation:
PMID:  23484757     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Changes in technology can often affect society and models of industry. The broad expectations for 'genomics' that were highly publicized during the previous decade have not materialized at the rate predicted. However, with the completion of the human genome, it is now possible to identify individual subject DNA profiles using platforms that measure thousands of genetic variants simultaneously and at a diminishing cost. Genome-wide screening affects two important components for success of the pharmaceutical industry. The first is drug discovery with the identification and selection of the right target for a disease or medical indication. The second involves crucial decisions required during drug development, related to proof of efficacy sufficient enough to support the enormous cost commitment for drug development. Using Alzheimer's disease as an example, the combined application of genome-wide screening, candidate gene analyses and efficacy pharmacogenetics is presented. The drivers for the industry for an evolution of present drug development come from the economic and regulatory environments, each of which are changing. The anticipated successes are effective and safe medicines for unmet medical needs, with a framework for sustaining drug pipelines.
Authors:
Allen D Roses
Related Documents :
8139377 - Levels of viral glycoprotein reflect enhanced effectiveness of combined drug treatments.
16867997 - In vitro inhibitory effect of antituberculosis drugs on clinical and environmental stra...
23820967 - Vital signs: overdoses of prescription opioid pain relievers and other drugs among wome...
20595497 - Short course combination therapy for giardiasis after nitroimidazole failure.
12847757 - Generalized pustules in a healthy woman.
24426237 - Cytotoxicity of liposomal paclitaxel in breast cancer cell line mcf-7.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert opinion on drug discovery     Volume:  2     ISSN:  1746-0441     ISO Abbreviation:  Expert Opin Drug Discov     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2013-03-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101295755     Medline TA:  Expert Opin Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  489-501     Citation Subset:  -    
Affiliation:
Senior Vice President, Pharmacogenetics, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709, USA. allen.d.roses@gsk.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ligand efficiency indices for effective drug discovery.
Next Document:  Autoradiography: high-resolution molecular imaging in pharmaceutical discovery and development.